

<u>L4</u>	(anti-cd40)same(vaccin\$ or adjuvant\$)same (link\$ or conjugat\$)	21	<u>L4</u>
<u>L3</u>	(anti-cd40)same(vaccin\$ or adjuvant\$)	95	<u>L3</u>
<u>L2</u>	L1 and (cd40 or anti-cd40 or cd40L or cd154 or cd40 adj ligand)	15	<u>L2</u>
<u>L1</u>	heath.in.	3459	<u>L1</u>

END OF SEARCH HISTORY

Refine Search

Search Results -

Term	Documents
BANGKOK	960
BANGKOKS	0
(2 AND BANGKOK).PGPB,USPT,EPAB,JPAB,DWPI.	1
(L2 AND BANGKOK).PGPB,USPT,EPAB,JPAB,DWPI.	1

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L4

Search History

DATE: Monday, March 05, 2007
 [Purge Queries](#)
 [Printable Copy](#)
 [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ

<u>L4</u>	L2 and bangkok	1	<u>L4</u>
<u>L3</u>	L2 and influenza	2	<u>L3</u>
<u>L2</u>	L1 and (cd40L or cd40 or cd40 adj ligand)	14	<u>L2</u>
<u>L1</u>	heath.in.	3459	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 2 of 2 returned.**

☐ 1. [20060165690](#). 10 Dec 03. 27 Jul 06. Vaccine comprising an antigen conjugated to low valency anti-cd40 or anti-cd28 antibodies. [Heath](#); Andrew, et al. 424/144.1; A61K39/395 20060101

☐ 2. [20020136722](#). 28 Jan 02. 26 Sep 02. Vaccination method. [Heath](#), Andrew William. 424/144.1; A61K039/395.

[Generate Collection](#)[Print](#)

Term	Documents
INFLUENZA	29511
INFLUENZAS	87
(2 AND INFLUENZA).PGPB,USPT,EPAB,JPAB,DWPI.	2
(L2 AND INFLUENZA).PGPB,USPT,EPAB,JPAB,DWPI.	2

[Prev Page](#) [Next Page](#) [Go to Doc#](#)

b 410

05mar07 12:46:00 User208760 Session D2833.1
\$1.00 0.287 DialUnits File1
\$1.00 Estimated cost File1
\$0.02 TELNET
\$1.02 Estimated cost this search
\$1.02 Estimated total session cost 0.287 DialUnits

File 410:Dialog Comm.-of-Interest Newsletters 2007 /Feb
(c) 2007 Dialog

Set Items Description
--- -----

? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,73,155,399

05mar07 12:46:05 User208760 Session D2833.2
\$0.00 0.156 DialUnits File410
\$0.00 Estimated cost File410
\$0.02 TELNET
\$0.02 Estimated cost this search
\$1.04 Estimated total session cost 0.443 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:BIOSIS Previews(R) 1926-2007/Feb W4
(c) 2007 The Thomson Corporation

*File 5: BIOSIS has been enhanced with archival data. Please see
HELP NEWS 5 for information.

File 73:EMBASE 1974-2007/Mar 02
(c) 2007 Elsevier B.V.

File 155:MEDLINE(R) 1950-2007/Mar 01
(c) format only 2007 Dialog

File 399:CA SEARCH(R) 1967-2007/UD=14610
(c) 2007 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

Set Items Description
--- -----

? e au=heath andrew ?

Ref	Items	Index-term
E1	9	AU=HEATH AMY T
E2	31	AU=HEATH ANDREW
E3	0	*AU=HEATH ANDREW ?
E4	211	AU=HEATH ANDREW C
E5	3	AU=HEATH ANDREW S
E6	45	AU=HEATH ANDREW W
E7	1	AU=HEATH ANDREW WILLIAM
E8	1	AU=HEATH ANDY
E9	1	AU=HEATH ANNA
E10	1	AU=HEATH ANNE K
E11	13	AU=HEATH ANNE-LOUISE M
E12	2	AU=HEATH ANNEMARIE

Enter P or PAGE for more

? s e2-e7

31	AU=HEATH ANDREW
0	AU=HEATH ANDREW ?
211	AU=HEATH ANDREW C
3	AU=HEATH ANDREW S

45 AU=HEATH ANDREW W
 1 AU=HEATH ANDREW WILLIAM
 S1 291 E2-E7
 ? s s1 and (cd40 or cd40L or cd40(W)ligand or cd154)
 291 S1
 30151 CD40
 7436 CD40L
 30151 CD40
 489033 LIGAND
 14224 CD40(W)LIGAND
 3402 CD154
 S2 27 S1 AND (CD40 OR CD40L OR CD40(W)LIGAND OR CD154)
 ? rd s2
 S3 23 RD S2 (unique items)
 ? rd s3
 S4 23 RD S3 (unique items)
 ? t s4/3/all

4/3/1 (Item 1 from file: 5)
 DIALOG(R)File 5:BIOSIS Previews(R)
 (c) 2007 The Thomson Corporation. All rts. reserv.

19236805 BIOSIS NO.: 200600582200
 Antibodies against cell surface antigens as very potent immunological
 adjuvants
 AUTHOR: Barr Tom; Carring Jennifer; Hatzifoti Caterina; Heath Andrew
 W (Reprint)
 AUTHOR ADDRESS: Univ Sheffield, Sch Med, Unit Infect and Immun, Beech Hill
 Rd, Sheffield S10 2RX, S Yorkshire, UK**UK
 AUTHOR E-MAIL ADDRESS: a.w.heath@ef.ac.uk
 JOURNAL: Vaccine 24 (Suppl. 2): pS20-S21 APR 12 2006 2006
 ISSN: 0264-410X
 DOCUMENT TYPE: Article
 RECORD TYPE: Abstract
 LANGUAGE: English

4/3/2 (Item 2 from file: 5)
 DIALOG(R)File 5:BIOSIS Previews(R)
 (c) 2007 The Thomson Corporation. All rts. reserv.

19091368 BIOSIS NO.: 200600436763
 Co-stimulatory agonists as immunological adjuvants
 AUTHOR: Barr Tom A; Carring Jennifer; Heath Andrew W (Reprint)
 AUTHOR ADDRESS: Univ Sheffield, Sch Med, Div Genom Med, Acad Unit Infect
 and Immun, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, UK**UK
 AUTHOR E-MAIL ADDRESS: tom.barr@ed.ac.uk; j.u.carlring-wright@shef.ac.uk;
 a.w.heath@sheffield.ac.uk
 JOURNAL: Vaccine 24 (17): p3399-3407 APR 24 2006 2006
 ISSN: 0264-410X
 DOCUMENT TYPE: Article; Literature Review
 RECORD TYPE: Abstract
 LANGUAGE: English

4/3/3 (Item 3 from file: 5)
 DIALOG(R)File 5:BIOSIS Previews(R)
 (c) 2007 The Thomson Corporation. All rts. reserv.

18411710 BIOSIS NO.: 200510106210
 CD40 antibody as a potent immunological adjuvant: CD40 antibody
 provides the CD40 signal to B cells, but does not substitute for T

cell help in responses to TD antigens
AUTHOR: Barr Tom A (Reprint); Carlring Jennifer; Heath Andrew W
AUTHOR ADDRESS: Univ Edinburgh, IIR, Kings Bldg, W Mains Rd, Edinburgh EH9
3JT, Midlothian, UK**UK
AUTHOR E-MAIL ADDRESS: a.w.heath@shef.ac.uk
JOURNAL: Vaccine 23 (26): p3477-3482 MAY 16 05 2005
ISSN: 0264-410X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

17352216 BIOSIS NO.: 200300309705
A potent adjuvant effect of ***CD40*** antibody attached to antigen.
AUTHOR: Barr Tom A; McCormick Adele L; Carlring Jennifer; Heath Andrew
W (Reprint)
AUTHOR ADDRESS: Division of Genomic Medicine, Academic Unit of Infection
and Immunity, Medical School, University of Sheffield, Beech Hill Road,
Sheffield, S10 2RX, UK**UK
AUTHOR E-MAIL ADDRESS: A.W.Heath@Shef.ac.uk
JOURNAL: Immunology 109 (1): p87-92 May 2003 2003
MEDIUM: print
ISSN: 0019-2805
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16040098 BIOSIS NO.: 200100211937
Stimulation of dendritic cells via CD40 enhances immune responses to
Mycobacterium tuberculosis infection
AUTHOR: Demangel Caroline; Palendira Umaimainthan; Feng Carl G; Heath
Andrew W; Bean Andrew G D; Britton Warwick J (Reprint)
AUTHOR ADDRESS: Centenary Institute of Cancer Medicine and Cell Biology,
Newtown, NSW, 2042, Australia**Australia
JOURNAL: Infection and Immunity 69 (4): p2456-2461 April, 2001 2001
MEDIUM: print
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

15578653 BIOSIS NO.: 200000296966
Early myeloid cells are high producers of nitric oxide upon CD40 plus
IFN-gamma stimulation through a mechanism dependent on endogenous
TNF-alpha and IL-1alpha
AUTHOR: Angulo Inigo; Rullas Joaquin; Campillo Jose Antonio; Obregon Eva;
Heath Andrew; Howard Maureen; Munoz-Fernandez Maria Angeles; Subiza
Jose Luis (Reprint)

AUTHOR ADDRESS: Department of Immunology, Hospital Clinico San Carlos,
E-28040, Madrid, Spain**Spain
JOURNAL: European Journal of Immunology 30 (5): p1263-1271 May, 2000 2000
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

15185521 BIOSIS NO.: 199900445181
Cell surface expression of CD154 inhibits alloantibody responses: A
mechanism for the prevention of autoimmune responses against activated T
cells?
AUTHOR: McCormick Adele Louise (Reprint); Santos-Argumedo Leopoldo; Thomas
Mark Stephen (Reprint); Heath Andrew William (Reprint)
AUTHOR ADDRESS: Division of Molecular and Genetic Medicine, University of
Sheffield Medical School, Sheffield, UK**UK
JOURNAL: Cellular Immunology 195 (2): p157-161 Aug. 1, 1999 1999
MEDIUM: print
ISSN: 0008-8749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

15095072 BIOSIS NO.: 199900354732
Enhanced in vivo immune responses to bacterial lipopolysaccharide by
exogenous CD40 stimulation
AUTHOR: Barr Tom A; Heath Andrew W (Reprint)
AUTHOR ADDRESS: Division of Molecular and Genetic Medicine, University of
Sheffield Medical School, Beech Hill Rd., F-Floor, Sheffield, S10 2RX, UK
**UK
JOURNAL: Infection and Immunity 67 (7): p3637-3640 July, 1999 1999
MEDIUM: print
ISSN: 0019-9567
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

14553595 BIOSIS NO.: 199800347842
Arrest of B lymphocyte terminal differentiation by CD40 signaling:
Mechanism for lack of antibody-secreting cells in germinal centers
AUTHOR: Randall Troy D (Reprint); Heath Andrew W; Santos-Argumedo
Leopoldo; Howard Maureen C; Weissman Irving L; Lund Frances E
AUTHOR ADDRESS: Trudeau Inst., Saranac Lake, NY 12983, USA**USA
JOURNAL: Immunity 8 (6): p733-742 June, 1998 1998
MEDIUM: print
ISSN: 1074-7613

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

14284683 BIOSIS NO.: 199800078930
Enhancement of T cell-independent immune responses in vivo by CD40
antibodies
AUTHOR: Dullforce Per (Reprint); Sutton Debbie C; Heath Andrew W
AUTHOR ADDRESS: Div. Molecular Genetic Med., Univ. Sheffield Med. Sch.,
Beech Hill Road, Sheffield S10 2RX, UK**UK
JOURNAL: Nature Medicine 4 (1): p88-91 Jan., 1998 1998
MEDIUM: print
ISSN: 1078-8956
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

13701562 BIOSIS NO.: 199799335622
CD40 signaling induces interleukin-4-independent IgE switching in
vivo
AUTHOR: Ferlin Walter G; Severinson Eva; Stroem Lena; Heath Andrew W;
Coffman Robert L; Ferrick David A; Howard Maureen C (Reprint)
AUTHOR ADDRESS: DNAX Res. Inst., 901 California Ave., Palo Alto, CA
94304-1104, USA**USA
JOURNAL: European Journal of Immunology 26 (12): p2911-2915 1996 1996
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

13613610 BIOSIS NO.: 199699247670
Differential effects of transforming growth factor-beta-1 on IgA vs IgG2b
production by lipopolysaccharide-stimulated lymph node B cells: A
comparative study with spleen B cells
AUTHOR: Garcia Belen; Rodriguez Rosa; Angulo Inigo; Heath Andrew W;
Howard Maureen C; Subiza Jose L (Reprint)
AUTHOR ADDRESS: Dep. Immunol., Hosp. Univ. San Carlos, E-28040 Madrid,
Spain**Spain
JOURNAL: European Journal of Immunology 26 (10): p2364-2370 1996 1996
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

12928641 BIOSIS NO.: 199598396474

CD40 function as defined by the in vivo administration of anti-
CD40 mAb

BOOK TITLE: The 9th International Congress of Immunology

AUTHOR: Ferlin Walter G (Reprint); Heath Andrew W; Howard Maureen
(Reprint)

BOOK AUTHOR/EDITOR: 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY

AUTHOR ADDRESS: DNAX Res. Inst. Palo Alto, CA, USA**USA

p264 1995

BOOK PUBLISHER: 9th International Congress of Immunology {a}, San
Francisco, California, USA

CONFERENCE/MEETING: Meeting Sponsored by the American Association of
Immunologists and the International Union of Immunological Societies San
Francisco, California, USA July 23-29, 1995; 19950723

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

4/3/14 (Item 14 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

12423298 BIOSIS NO.: 199497444583

Monoclonal antibodies to murine CD40 define two distinct functional
epitopes

AUTHOR: Heath Andrew W; Wu Wei Wei; Howard Maureen C (Reprint)

AUTHOR ADDRESS: DNAX Res. Inst., 901 California Ave., Palo Alto, CA 94304,
USA**USA

JOURNAL: European Journal of Immunology 24 (8): p1828-1834 1994 1994

ISSN: 0014-2980

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

4/3/15 (Item 15 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

12383212 BIOSIS NO.: 199497404497

Antibodies to murine CD40 protection normal and malignant B cells
from induced growth arrest

AUTHOR: Santos-Argumedo Leopoldo; Gordon John; Heath Andrew W; Howard
Maureen (Reprint)

AUTHOR ADDRESS: DNAX Res. Inst., 901 California Ave., Palo Alto, CA 94304,
USA**USA

JOURNAL: Cellular Immunology 156 (2): p272-285 1994 1994

ISSN: 0008-8749

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

4/3/16 (Item 16 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

12318313 BIOSIS NO.: 199497339598

Interaction of CD40 ligand with a B cell lymphoma inhibits

differentiation and immunoglobulin secretion
AUTHOR: Randall Troy D (Reprint); Heath Andrew; Lund Frances E;
Howard Maureen; Weissman Irving
AUTHOR ADDRESS: Dep. Pathol., Stanford Univ., Stanford, CA 94305, USA**USA
JOURNAL: Journal of Cellular Biochemistry Supplement 0 (18D): p433 1994
1994
CONFERENCE/MEETING: Keystone Symposium on Lymphocyte Activation Keystone,
Colorado, USA April 10-17, 1994; 19940410
ISSN: 0733-1959
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Citation
LANGUAGE: English

4/3/17 (Item 17 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

12119315 BIOSIS NO.: 199497140600
Immunoglobulin signal transduction guides the specificity of B cell-T cell
interactions and is blocked in tolerant self-reactive B cells
AUTHOR: Cooke Michael P (Reprint); Heath Andrew W; Shokat Kevan M
(Reprint); Zeng Yongjun (Reprint); Finkelman Fred D; Linsley Peter S;
Howard Maureen; Goodnow Christopher C (Reprint)
AUTHOR ADDRESS: Howard Hughes Med. Inst. Res. Lab., Beckman Cent. Mol.
Genet. Med., Stanford Univ. Med. Cent., Stanford, CA 94305-5428, USA**USA
JOURNAL: Journal of Experimental Medicine 179 (2): p425-438 1994 1994
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

12104726 BIOSIS NO.: 199497126011
Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit
proliferation of B lymphoma cells
AUTHOR: Heath Andrew W; Chang Ray; Harada Nobuyuki; Santos-Argumedo
Leopoldo; Gordon John; Hannum Charles; Campbell David; Shanafelt Armen B;
Clark Edward A
AUTHOR ADDRESS: Maureen Howard, DNAX Research Inst., 901 California Ave.,
Palo Alto, CA 94304, USA**USA
JOURNAL: Cellular Immunology 152 (2): p468-480 1993 1993
ISSN: 0008-8749
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/19 (Item 19 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

11573096 BIOSIS NO.: 199345004076
Antibodies to murine CD40 stimulate normal B cells but inhibit
proliferation of B lymphoma
AUTHOR: Howard Maureen (Reprint); Harada Nobuyuki; Santos-Argumedo Leopoldo
(Reprint); Torres Raul; Clark Edward; Heath Andrew (Reprint)
AUTHOR ADDRESS: DNAX Res. Inst., Palo Alto, CA 94304, USA**USA

JOURNAL: Journal of Cellular Biochemistry Supplement 0 (17 PART B): p50
1993
CONFERENCE/MEETING: Keystone Symposium on Cytokines and Cytokine Receptors:
From Cloning to the Clinic Keystone, Colorado, USA January 31-February 7,
1993; 19930131
ISSN: 0733-1959
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: English

4/3/20 (Item 20 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

11552613 BIOSIS NO.: 199344115518
Two functionally distinct epitopes on murine CD40
AUTHOR: Heath Andrew (Reprint); Howard Maureen (Reprint); Gordon John
AUTHOR ADDRESS: DNAX Res. Inst., Palo Alto, CA 94304, USA**USA
JOURNAL: Journal of Cellular Biochemistry Supplement 0 (17 PART B): p214
1993
CONFERENCE/MEETING: Keystone Symposium on Molecular Aspects of B Lymphocyte
Differentiation Taos, New Mexico, USA February 1-8, 1993; 19930201
ISSN: 0733-1959
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: English

4/3/21 (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

15346986 PMID: 15732532
Adjuvanticity of anti- ***CD40*** in vaccine development.
Cairing Jennifer; Barr Tom; Heath Andrew W
University of Sheffield School of Medicine and Biomedical Sciences, Unit
of Infection and Immunity, Division of Genomic Medicine, Sheffield, UK.
Current opinion in molecular therapeutics (England) Feb 2005, 7 (1)
p73-7, ISSN 1464-8431--Print Journal Code: 100891485
Publishing Model Print
Document type: Journal Article; Review
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

4/3/22 (Item 2 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

15028918 PMID: 15308355
CD40 antibody as an adjuvant induces enhanced T cell responses.
Carlring Jennifer; Barr Tom A; McCormick Adele L; Heath Andrew W
Infection and Immunity: Division of Genomic Medicine, F Floor, University
of Sheffield Medical School, Beech Hill Rd, Sheffield S10 2RX, UK.
Vaccine (Netherlands) Sep 3 2004, 22 (25-26) p3323-8, ISSN
0264-410X--Print Journal Code: 8406899
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM

Record type: MEDLINE; Completed

4/3/23 (Item 3 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

14184048 PMID: 12594842

Anti-CD28 has a potent adjuvant effect on the antibody response to soluble antigens mediated through CTLA-4 by-pass.

Carlring Jennifer; Barr Tom A; Buckle Anne-Marie; Heath Andrew W
Division of Genomic Medicine, University of Sheffield Medical School,
Sheffield, GB.

European journal of immunology (Germany) Jan 2003, 33 (1) p135-42,
ISSN 0014-2980--Print Journal Code: 1273201

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

? s anti(W)cd40(5n) (adjuvant? or vaccin?) (10n) (link? or conjugat?)

Processing

1849685 ANTI

30151 CD40

233934 ADJUVANT?

537398 VACCIN?

1358886 LINK?

377674 CONJUGAT?

S5 3 ANTI(W)CD40(5N) (ADJUVANT? OR VACCIN?) (10N) (LINK? OR
CONJUGAT?)

? rd s5

S6 3 RD S5 (unique items)

? t s6/3/all

6/3/1 (Item 1 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

145246949 CA: 145(13)246949u JOURNAL

Antibodies against cell surface antigens as very potent immunological
adjuvants

AUTHOR(S): Barr, Tom; Carlring, Jennifer; Hatzifoti, Caterina; Heath,
Andrew W.

LOCATION: Unit of Infection and Immunity, University of Sheffield Medical
School, Sheffield, UK, S10 2RX

JOURNAL: Vaccine (Vaccine) DATE: 2006 VOLUME: 24 NUMBER: Suppl. 2

PAGES: S2/20-S2/21 CODEN: VACCDE ISSN: 0264-410X

PUBLISHER ITEM IDENTIFIER: 0264-410X(05)00155-6 LANGUAGE: English

PUBLISHER: Elsevier B.V.

6/3/2 (Item 2 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

141052853 CA: 141(4)52853e PATENT

Vaccine comprising an antigen conjugated to low valency anti-CD40 or
anti-CD28 antibodies

INVENTOR(AUTHOR): Heath, Andrew; Laing, Peter

LOCATION: UK,

ASSIGNEE: Adjuvantix Limited

PATENT: PCT International ; WO 200452396 A1 DATE: 20040624

APPLICATION: WO 2003GB5389 (20031210) *GB 200228796 (20021211)

PAGES: 31 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/39A; A61K-039/14B; A61K-039/02B; A61K-039/12B;
A61K-039/005B; A61K-039/015B; A61P-031/00B; C07K-016/28B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE;
GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT;
LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT; RO;
RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC;
VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; SD; SL
; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE;
SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/3 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

140422398 CA: 140(26)422398w PATENT

Adjuvant acty of carrier proteins conjugated to antibodies against CD40
or CD28

INVENTOR(AUTHOR): Heath, Andrew

LOCATION: UK,

ASSIGNEE: Adjuvantix Limited

PATENT: PCT International ; WO 200441866 A1 DATE: 20040521

APPLICATION: WO 2003GB4738 (20031103) *GB 200225736 (20021105)

PAGES: 51 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C07K-016/28A; A61K-039/39B; A61K-039/385B; A61K-039/44B;
C12N-005/16B; C07K-019/00B; C07K-014/195B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE;
GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT;
LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT; RO;
RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC;
VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD DESIGNATED REGIONAL: BW; GH; GM
; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE;
DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR;
BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

? s anti(W)cd40(10n)(adjuvant?)

1849685 ANTI

30151 CD40

233934 ADJUVANT?

S7 36 ANTI(W)CD40(10N)(ADJUVANT?)

? rd s7

S8 18 RD S7 (unique items)

? t s8/3/all

8/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:BIOSIS Previews(R)

(c) 2007 The Thomson Corporation. All rts. reserv.

18919446 BIOSIS NO.: 200600264841

Circumventing tolerance at the T cell or the antigen-presenting cell

surface: Antibodies that ligate CD40 and OX40 have different effects

AUTHOR: Hochweller Kristin; Sweeney Claire H; Anderton Stephen M (Reprint)

AUTHOR ADDRESS: Univ Edinburgh, Sch Biol Sci, Inst Immunol and Infect Res,

Kings Bldg,W Mains Rd, Edinburgh EH9 3JT, Midlothian, UK**UK

AUTHOR E-MAIL ADDRESS: steve.anderton@ed.ac.uk

JOURNAL: European Journal of Immunology 36 (2): p389-396 FEB 2006 2006

ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

18411710 BIOSIS NO.: 200510106210
CD40 antibody as a potent immunological adjuvant: CD40 antibody provides the CD40 signal to B cells, but does not substitute for T cell help in responses to TD antigens
AUTHOR: Barr Tom A (Reprint); Carlring Jennifer; Heath Andrew W
AUTHOR ADDRESS: Univ Edinburgh, IIR, Kings Bldg, W Mains Rd, Edinburgh EH9 3JT, Midlothian, UK**UK
AUTHOR E-MAIL ADDRESS: a.w.heath@shef.ac.uk
JOURNAL: Vaccine 23 (26): p3477-3482 MAY 16 05 2005
ISSN: 0264-410X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

17755153 BIOSIS NO.: 200400125910
Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand.
AUTHOR: Huang Hsing-I; Wu Ping-Yi; Teo Chin-Yee; Chen Min-Nan; Chen Yi-Chau; Silin Dmytro; Tao Mi-Hua (Reprint)
AUTHOR ADDRESS: Institute of Biomedical Sciences, Academia Sinica, 128 Yen-Chiu-Yuan Road, Section 2, Taipei, 115, Taiwan**Taiwan
AUTHOR E-MAIL ADDRESS: bmtao@ibms.sinica.edu.tw
JOURNAL: International Journal of Cancer 108 (5): p696-703 20 February, 2004 2004
MEDIUM: print
ISSN: 0020-7136
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

17154863 BIOSIS NO.: 200300113582
Distinctive maturation of in vitro versus in vivo anti-CD40 mAb-matured dendritic cells in mice.
AUTHOR: Frleta Davor; Lin Jack T; Quezada Sergio A; Wade Terri K; Barth Richard J; Noelle Randolph J; Wade William F (Reprint)
AUTHOR ADDRESS: Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, NH, 03756, USA**USA
AUTHOR E-MAIL ADDRESS: William.F.Wade@Dartmouth.Edu
JOURNAL: Journal of Immunotherapy 26 (1): p72-84 January-February 2003 2003
MEDIUM: print
ISSN: 1524-9557 _ (ISSN print)

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16983658 BIOSIS NO.: 200200577169
Immune tolerance after delivery of dying cells to dendritic cells in situ
AUTHOR: Liu Kang; Iyoda Tomonori; Saternus Marzena; Kimura Yukino; Inaba
Kayo; Steinman Ralph M (Reprint)
AUTHOR ADDRESS: Laboratory of Cellular Physiology and Immunology, Chris
Browne Center for Immunology and Immune Diseases, Rockefeller University,
New York, NY, 10021, USA**USA
JOURNAL: Journal of Experimental Medicine 196 (8): p1091-1097 October 21,
2002 2002
MEDIUM: print
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16965153 BIOSIS NO.: 200200558664
Systemic treatment with anti-CD40 antibody stimulates Langerhans cell
migration from the skin
AUTHOR: Jolles S (Reprint); Christensen J; Holman M; Klaus G B; Ager A
AUTHOR ADDRESS: Division of Cellular Immunology, National Institute for
Medical Research, The Ridgeway, Mill Hill, London, NW7 1AA, UK**UK
JOURNAL: Clinical and Experimental Immunology 129 (3): p519-526 September,
2002 2002
MEDIUM: print
ISSN: 0009-9104
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

16924198 BIOSIS NO.: 200200517709
Intranasal administration of a synthetic peptide vaccine encapsulated in
liposome together with an anti-CD40 antibody induces protective immunity
against influenza A virus in mice
AUTHOR: Ninomiya Ai; Ogasawara Kazumasa (Reprint); Kajino Kiichi; Takada
Ayato; Kida Hiroshi
AUTHOR ADDRESS: Second Department of Pathology, School of Medicine, Shiga
University of Medical Science, Ohtsu, 520-2192, Japan**Japan
JOURNAL: Vaccine 20 (25-26): p3123-3129 19 August, 2002 2002
MEDIUM: print
ISSN: 0264-410X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2007 The Thomson Corporation. All rts. reserv.

15596578 BIOSIS NO.: 200000314891
Potent adjuvant effect by anti-CD40 in collagen-induced
arthritis. Enhanced disease is accompanied by increased production of
collagen type-II reactive IgG2a and IFN-gamma
AUTHOR: Tellander Annamaria C (Reprint); Michaelsson Erik; Brunmark
Charlott; Andersson Mikael
AUTHOR ADDRESS: Active Biotech Research AB, SE-22007, Lund, Sweden**Sweden
JOURNAL: Journal of Autoimmunity 14 (4): p295-302 J, 2000 2000
MEDIUM: print
ISSN: 0896-8411
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

8/3/9 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2007 Elsevier B.V. All rts. reserv.

13033986 EMBASE No: 2005094538
Adjuvantcity of anti-CD40 in vaccine development
Carlring J.; Barr T.; Heath A.W.
A.W. Heath, Univ. of Sheffield Sch. of Medicine, Unit of Infection and
Immunity, Division of Genomic Medicine, Beech Hill Road, Sheffield S10
2RX United Kingdom
AUTHOR EMAIL: a.w.heath@sheffield.ac.uk
Current Opinion in Molecular Therapeutics (CURR. OPIN. MOL. THER.) (
United Kingdom) 2005, 7/1 (73-77)
CODEN: CUOTF ISSN: 1464-8431
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 31

8/3/10 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

20779004 PMID: 16425257
Combined prophylactic and therapeutic cancer vaccine: enhancing CTL
responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Qian Jiahua; Dong Yujun; Pang Yuk-Ying S; Ibrahim Ramy; Berzofsky Jay A;
Schiller John T; Khleif Samir N
Vaccine Branch, NCI, National Naval Medical Center, Bldg 8, Bethesda, MD
20892, USA. qinanj@mail.nih.gov
International journal of cancer. Journal international du cancer (United
States) Jun 15 2006, 118 (12) p3022-9, ISSN 0020-7136--Print
Journal Code: 0042124
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/11 (Item 2 from file: 155)

DIALOG(R)File 155:MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.

15346986 PMID: 15732532

Adjuvanticity of ***anti*** - ***cD40*** in vaccine development.
Cairing Jennifer; Barr Tom; Heath Andrew W
University of Sheffield School of Medicine and Biomedical Sciences, Unit
of Infection and Immunity, Division of Genomic Medicine, Sheffield, UK.
Current opinion in molecular therapeutics (England) Feb 2005, 7 (1)
p73-7, ISSN 1464-8431--Print Journal Code: 100891485
Publishing Model Print
Document type: Journal Article; Review
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

8/3/12 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

145395460 CA: 145(20)395460e PATENT
Epidermal growth factor receptor immunogens for tumor therapy
INVENTOR(AUTHOR): Steinaa, Lucilla; Renard, Valery
LOCATION: Den.
ASSIGNEE: Pharmexa A/S
PATENT: PCT International ; WO 2006102901 A2 DATE: 20061005
APPLICATION: WO 2006DK184 (20060330) *DK 2005448 (20050331) *US
2005PV667441 (20050331)
PAGES: 69pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK;
LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ;
OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR;
TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

8/3/13 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

145246949 CA: 145(13)246949u JOURNAL
Antibodies against cell surface antigens as very potent immunological
adjuvants
AUTHOR(S): Barr, Tom; Carlring, Jennifer; Hatzifoti, Caterina; Heath,
Andrew W.
LOCATION: Unit of Infection and Immunity, University of Sheffield Medical
School, Sheffield, UK, S10 2RX
JOURNAL: Vaccine (Vaccine) DATE: 2006 VOLUME: 24 NUMBER: Suppl. 2
PAGES: S2/20-S2/21 CODEN: VACCDE ISSN: 0264-410X
PUBLISHER ITEM IDENTIFIER: 0264-410X(05)00155-6 LANGUAGE: English
PUBLISHER: Elsevier B.V.

8/3/14 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

141052853 CA: 141(4)52853e PATENT

Vaccine comprising an antigen conjugated to low valency anti-CD40 or anti-CD28 antibodies

INVENTOR(AUTHOR): Heath, Andrew; Laing, Peter

LOCATION: UK,

ASSIGNEE: Adjuvantix Limited

PATENT: PCT International ; WO 200452396 A1 DATE: 20040624

APPLICATION: WO 2003GB5389 (20031210) *GB 200228796 (20021211)

PAGES: 31 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/39A; A61K-039/14B; A61K-039/02B; A61K-039/12B;
A61K-039/005B; A61K-039/015B; A61P-031/00B; C07K-016/28B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE;
GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT;
LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT; RO;
RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC;
VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; SD; SL;
; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH;
CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE;
SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/15 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

140422398 CA: 140(26)422398w PATENT

Adjuvant acty of carrier proteins conjugated to antibodies against CD40 or CD28

INVENTOR(AUTHOR): Heath, Andrew

LOCATION: UK,

ASSIGNEE: Adjuvantix Limited

PATENT: PCT International ; WO 200441866 A1 DATE: 20040521

APPLICATION: WO 2003GB4738 (20031103) *GB 200225736 (20021105)

PAGES: 51 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: C07K-016/28A; A61K-039/39B; A61K-039/385B; A61K-039/44B;
C12N-005/16B; C07K-019/00B; C07K-014/195B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE;
GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT;
LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT; RO;
RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC;
VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD DESIGNATED REGIONAL: BW; GH; GM;
; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE;
DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR;
BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

8/3/16 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2007 American Chemical Society. All rts. reserv.

137062164 CA: 137(5)62164n PATENT

Pneumococcal vaccine comprising capsular polysaccharide plus anti-CD40 antibody

INVENTOR(AUTHOR): Heath, Andrew William

LOCATION: UK,

PATENT: U.S. Pat. Appl. Publ. ; US 20020086026 A1 DATE: 20020704
APPLICATION: US 938477 (20010824) *US 878348 (19970618)
PAGES: 14 pp., Cont. of U.S. Ser. No. 878,348, abandoned. CODEN: USXXCO
LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: 424184100; A61K-039/00A; C07H-021/04B; C12P-021/02B;
C12N-005/06B

8/3/17 (Item 6 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

136004661 CA: 136(1)4661r JOURNAL
CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in
the absence of tumor-antigen vaccination
AUTHOR(S): Kedl, Ross M.; Jordan, Michael; Potter, Terence; Kappler, John
; Marrack, Philippa; Dow, Steven
LOCATION: Cancer Research Institute, Department of Immunology, National
Jewish Medical and Research Center, University of Colorado Health Sciences
Center, Denver, CO, 80206, USA
JOURNAL: Proc. Natl. Acad. Sci. U. S. A. DATE: 2001 VOLUME: 98
NUMBER: 19 PAGES: 10811-10816 CODEN: PNASA6 ISSN: 0027-8424
LANGUAGE: English PUBLISHER: National Academy of Sciences

8/3/18 (Item 7 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2007 American Chemical Society. All rts. reserv.

132106969 CA: 132(9)106969g PATENT
Chemokines as adjuvants of immune response
INVENTOR(AUTHOR): Caux, Christophe; Vanbervliet, Beatrice; Lebecque,
Serge; Vicari, Alain; Dieu, Marie-Caroline
LOCATION: Fr.
ASSIGNEE: Schering-Plough
PATENT: European Pat. Appl. ; EP 974357 A1 DATE: 20000126
APPLICATION: EP 98401799 (19980716)
PAGES: 16 pp. CODEN: EPXXDW LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-038/19A
DESIGNATED COUNTRIES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL;
SE; MC; PT; IE; SI; LT; LV; FI; RO
?

KWIC option is not available in file(s): 399

8/KWIC/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

...ABSTRACT: T cell resulting in prolonged T cell proliferation/survival, boosting the immune response. Thus agonistic ***anti*** - ***CD40*** and anti-OX40 might be viewed as "adjuvant antibodies" and have been shown in diverse experimental systems to either boost immune responses or ...

8/KWIC/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

...ABSTRACT: mimic T cell help. Simultaneous administration of recombinant IL-4 was unable to restore the adjuvant action of anti-***CD40*** in T cell depleted mice. However, CD40mAbs are effective adjuvants in CD154-/- mice, indicating that the antibodies are able to provide the CD40 stimulus to...

8/KWIC/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

...ABSTRACT: on antigen-presenting cells (APCs) is critical in promoting humoral and cellular immune responses. Agonistic ***anti*** - ***CD40*** monoclonal antibody and soluble CD40L can act as powerful adjuvants to promote vaccination, but usually require repeated high-dose treatment. In this study, we demonstrate...

8/KWIC/4 (Item 4 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

...ABSTRACT: to become adept at presenting antigen to and activating naive T lymphocytes. The use of ***anti*** - ***CD40*** antibodies as ***adjuvants*** for DC-based therapy has been advanced. Little is known as to how DC biology...

8/KWIC/5 (Item 5 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

...ABSTRACT: were deleted. The animals were also tolerant to challenge with OVA in complete Freund's ***adjuvant***. An agonistic ***anti*** - CD40 monoclonal antibody was then administered together with the OVA-loaded splenocytes, so that the dendritic...

8/KWIC/6 (Item 6 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

...ABSTRACT: not altered. These observations may have important implications for the mechanism of action of agonistic anti-CD40 antibodies, which have been used as an adjuvant in models of infection and experimental tumours and the primary immunodeficiency Hyper IgM syndrome caused...

8/KWIC/7 (Item 7 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

...ABSTRACT: NP366-374 effectively induced mucosal immunity to reduce virus replication in the lung, suggesting that anti-CD40 mAb also functioned as a mucosal ***adjuvant***. Interestingly, neither MHC class I- nor class II-deficient mice immunized intranasally with these materials...

8/KWIC/8 (Item 8 from file: 5)
DIALOG(R)File 5:(c) 2007 The Thomson Corporation. All rts. reserv.

Potent adjuvant effect by anti-CD40 in collagen-induced arthritis. Enhanced disease is accompanied by increased production of collagen type-II...

8/KWIC/9 (Item 1 from file: 73)
DIALOG(R)File 73:(c) 2007 Elsevier B.V. All rts. reserv.

Adjuvanticity of anti-CD40 in vaccine development

8/KWIC/10 (Item 1 from file: 155)
DIALOG(R)File 155:(c) format only 2007 Dialog. All rts. reserv.

... the CTL response to E7 could be significantly enhanced by coinjection of GM-CSF and anti-CD40 antibodies with chimeric VLP-E7E2 without ***adjuvant***. However, using the same combination, a low level of CD8(+) T cell response to E2...

8/KWIC/11 (Item 2 from file: 155)
DIALOG(R)File 155:(c) format only 2007 Dialog. All rts. reserv.

Adjuvanticity of ***anti*** - ***CD40*** in vaccine development.
?